November 7, 2023 – The Aalpha Reporter

Archive

India Data Center Market to Reach Investment of $9.96 Billion by 2028 – Arizton

India Data Center Market Research Report by Arizton Get Insights on 90+ Existing Data Centers and 75+ Upcoming Facilities across India. According to Arizton’s latest research report, the India data

Fluoropolymer Processing Aid Market Projected to Reach $1.7 Billion by 2028

Browse 243 market data Tables and 50 Figures spread through 233 Pages and in-depth TOC on “Fluoropolymer Processing Aid Market” Fluoropolymer Processing Aid Market by Polymer Type (PE, PP, PVC),

Respiratory Syncytial Virus (RSV) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Enanta, ReViral, Pfizer, Sanofi, BioComo

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Respiratory Syncytial Virus therapeutics landscape based

Geographic Atrophy Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Ionis, IVERIC bio, Apellis, Annexon, Novartis, Astellas

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 23+ key pharma and biotech companies are working on 25+ pipeline drugs in the Geographic Atrophy therapeutics landscape based on

Primary Biliary Cholangitis (PBC) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Genfit, CymaBay, Mirum, Gilead, Eli Lilly, Ohara

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 28+ key pharma and biotech companies are working on 28+ pipeline drugs in the Primary Biliary Cholangitis (PBC) therapeutics landscape

Glabellar Lines Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Revance Therapeutics, ATGC Biotech, AbbVie, Ipsen, Eirion

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, several major pharma and biotech companies are working on developing various drugs in the Glabellar Lines therapeutics landscape based on different

Cutaneous Lupus Erythematosus Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Gilead, Priothera, Sanofi, Merck, Centessa

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Cutaneous Lupus Erythematosus therapeutics landscape based

Dystrophic Epidermolysis Bullosa Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Phoenicis, Aegle, Anterogen, Abeona, Eloxx

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Dystrophic Epidermolysis Bullosa therapeutics landscape based

Diabetic Retinopathy Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Kodiak Sciences, Novartis, Regenxbio, OcuTerra, Bayer

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 55+ pipeline drugs in the Diabetic Retinopathy therapeutics landscape based on

Peripheral T-Cell Lymphomas (PTCL) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Acrotech, Verastem, Seattle Genetics, Ak

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 40+ key pharma and biotech companies are working on 40+ pipeline drugs in the Peripheral T-Cell Lymphomas (PTCL) therapeutics landscape

Archive

Loading, Please Wait!